Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ZVRA Stock Forecast 2026-2027
$8.93
Current Price
$502.74M
Market Cap
Buy 8
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ZVRA Price Targets
+191.2%
To High Target of $26.00
+157.6%
To Median Target of $23.00
+101.6%
To Low Target of $18.00
ZVRA Price Momentum
+5.2%
1 Week Change
+10.2%
1 Month Change
+10.9%
1 Year Change
-0.3%
Year-to-Date Change
-32.1%
From 52W High of $13.16
+44.3%
From 52W Low of $6.19
📊 TOP ANALYST CALLS
Did ZVRA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if KemPharm is one of their latest high-conviction picks.
Latest ZVRA Stock Price Targets & Analyst Predictions
Based on our analysis of 14 Wall Street analysts, ZVRA has a bullish consensus with a median price target of $23.00 (ranging from $18.00 to $26.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $8.93, the median forecast implies a 157.6% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Brandon Folkes at HC Wainwright & Co., projecting a 191.2% upside. Conversely, the most conservative target is provided by Jason N. Butler at JMP Securities, suggesting a 101.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ZVRA Analyst Ratings
8
Buy
0
Hold
0
Sell
ZVRA Price Target Range
Low
$18.00
Average
$23.00
High
$26.00
Current: $8.93
Latest ZVRA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ZVRA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 6, 2025 | Cantor Fitzgerald | Kristen Kluska | Overweight | Maintains | $24.00 |
| Nov 6, 2025 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $24.00 |
| Aug 13, 2025 | JMP Securities | Jason N. Butler | Market Outperform | Maintains | $18.00 |
| Jul 10, 2025 | Cantor Fitzgerald | Kristen Kluska | Overweight | Maintains | $29.00 |
| Jul 2, 2025 | HC Wainwright & Co. | Brandon Folkes | Buy | Initiates | $26.00 |
| May 14, 2025 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $25.00 |
| Mar 13, 2025 | HC Wainwright & Co. | Oren Livnat | Buy | Reiterates | $20.00 |
| Mar 13, 2025 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $25.00 |
| Mar 13, 2025 | Guggenheim | Eddie Hickman | Buy | Maintains | $22.00 |
| Mar 12, 2025 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $25.00 |
| Mar 12, 2025 | Citizens Capital Markets | Jason Butler | Market Outperform | Maintains | $18.00 |
| Nov 20, 2024 | HC Wainwright & Co. | Oren Livnat | Buy | Reiterates | $20.00 |
| Nov 14, 2024 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $23.00 |
| Oct 11, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $N/A |
| Oct 7, 2024 | Guggenheim | Buy | Initiates | $20.00 | |
| Oct 1, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $N/A |
| Sep 30, 2024 | HC Wainwright & Co. | Oren Livnat | Buy | Reiterates | $20.00 |
| Sep 24, 2024 | JMP Securities | Jason Butler | Market Outperform | Initiates | $17.00 |
| Sep 24, 2024 | Maxim Group | Jason McCarthy | Buy | Maintains | $25.00 |
| Sep 24, 2024 | Roth MKM | Jonathan Aschoff | Buy | Maintains | $21.00 |
Zevra Therapeutics, Inc. (ZVRA) Competitors
The following stocks are similar to KemPharm based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Zevra Therapeutics, Inc. (ZVRA) Financial Data
Zevra Therapeutics, Inc. has a market capitalization of $502.74M with a P/E ratio of 19.0x. The company generates $84.39M in trailing twelve-month revenue with a 41.9% profit margin.
Revenue growth is +605.4% quarter-over-quarter, while maintaining an operating margin of +15.9% and return on equity of +34.8%.
Valuation Metrics
Market Cap
$502.74M
Enterprise Value
$365.94M
P/E Ratio
19.0x
PEG Ratio
-0.2x
Price/Sales
6.0x
Growth & Margins
Revenue Growth (YoY)
+605.4%
Gross Margin
+95.2%
Operating Margin
+15.9%
Net Margin
+41.9%
EPS Growth
+605.4%
Financial Health
Cash/Price Ratio
+39.7%
Current Ratio
8.6x
Debt/Equity
47.1x
ROE
+34.8%
ROA
-7.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Zevra Therapeutics, Inc. (ZVRA) Business Model
About Zevra Therapeutics, Inc.
What They Do
Develops innovative therapies for unmet medical needs.
Business Model
Zevra Therapeutics generates revenue by developing and commercializing novel pharmaceutical therapies, particularly targeting rare and orphan diseases. The company invests in a robust pipeline of candidate drugs, aiming to provide transformative medical solutions that address gaps in current treatment options.
Additional Information
Zevra Therapeutics emphasizes collaboration with research institutions, healthcare professionals, and regulatory bodies to translate scientific discoveries into effective treatments. The company plays a crucial role in pharmaceutical innovation, enhancing patient outcomes and advancing the life sciences industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
59
CEO
Mr. Neil F. McFarlane
Country
United States
IPO Year
2021
Website
zevra.comZevra Therapeutics, Inc. (ZVRA) Latest News & Analysis
Latest News
Zevra Therapeutics, Inc. (ZVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
2 days ago
Quick Summary
Zevra Therapeutics, Inc. (ZVRA) presented at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its developments and strategic direction.
Why It Matters
Zevra Therapeutics' presentation may signal developments in their pipeline or strategy, influencing investor sentiment and stock performance in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Zevra Therapeutics reported Q3 FY25 revenues of $26.1M, a 605% YoY increase, nearing profitability. With a strong cash position and growth from MIPLYFFA, FY26 is projected for true profitability.
Why It Matters
Zevra Therapeutics' soaring revenue and impending profitability signal strong growth potential. With a solid cash position and expansion opportunities, ZVRA's valuation offers attractive upside for investors.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Zevra Therapeutics granted options for 53,000 shares to three new employees under its 2023 Employment Inducement Award Plan, with a four-year vesting schedule.
Why It Matters
Zevra's grant of stock options signals confidence in growth and retention of talent, potentially boosting performance and stock value, impacting investor sentiment positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Zevra Therapeutics appointed Alicia Secor to its Board of Directors and announced the retirement of Wendy Dixon, effective December 2, 2025.
Why It Matters
Alicia Secor's appointment to Zevra's Board could influence strategic direction and governance, impacting investor confidence and stock performance. Board changes often signal shifts in company priorities.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Zevra Therapeutics announced CFO R. LaDuane Clifton will resign effective December 31, 2025, to pursue other opportunities.
Why It Matters
Leadership changes can impact investor confidence and stock performance, especially in a commercial-stage company like Zevra Therapeutics, affecting strategic direction and financial stability.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Zevra Therapeutics, Inc. (ZVRA) will hold its Q3 2025 earnings call on November 5, 2025, at 4:30 PM EST, featuring key company executives and analysts from Cantor Fitzgerald and William Blair.
Why It Matters
The Q3 earnings call for Zevra Therapeutics on November 5, 2025, will provide insights into financial performance and strategic direction, impacting investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About ZVRA Stock
What is Zevra Therapeutics, Inc.'s (ZVRA) stock forecast for 2026?
Based on our analysis of 14 Wall Street analysts, Zevra Therapeutics, Inc. (ZVRA) has a median price target of $23.00. The highest price target is $26.00 and the lowest is $18.00.
Is ZVRA stock a good investment in 2026?
According to current analyst ratings, ZVRA has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.93. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ZVRA stock?
Wall Street analysts predict ZVRA stock could reach $23.00 in the next 12 months. This represents a 157.6% increase from the current price of $8.93. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Zevra Therapeutics, Inc.'s business model?
Zevra Therapeutics generates revenue by developing and commercializing novel pharmaceutical therapies, particularly targeting rare and orphan diseases. The company invests in a robust pipeline of candidate drugs, aiming to provide transformative medical solutions that address gaps in current treatment options.
What is the highest forecasted price for ZVRA Zevra Therapeutics, Inc.?
The highest price target for ZVRA is $26.00 from Brandon Folkes at HC Wainwright & Co., which represents a 191.2% increase from the current price of $8.93.
What is the lowest forecasted price for ZVRA Zevra Therapeutics, Inc.?
The lowest price target for ZVRA is $18.00 from Jason N. Butler at JMP Securities, which represents a 101.6% increase from the current price of $8.93.
What is the overall ZVRA consensus from analysts for Zevra Therapeutics, Inc.?
The overall analyst consensus for ZVRA is bullish. Out of 14 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $23.00.
How accurate are ZVRA stock price projections?
Stock price projections, including those for Zevra Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 18, 2026 11:19 AM UTC